Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.

Abstract evidence7 comparisonsAutomated source matching · not expert reviewed

Partial coverage · gaps are marked inside each comparison

Some results can be visualized; unassessed context remains visible.

Choose a comparison

7 comparisons · Each follows its own evidence.

What happened? exenatide-10 μg-twice-daily compared with sulfonylureas

One comparison, followed all the way through

exenatide-10 μg-twice-daily compared with sulfonylureas

incident hypertension

Follow the study

What was examined

exenatide-10 μg-twice-daily

Paper abstract · Abstract

sulfonylureas

Paper abstract · Abstract

Outcome named in the source

incident hypertension

Paper abstract · Abstract

The study design is not ready to draw

Comparison-level assignment evidence has not been extracted.

Open the paper record

Relative comparison

odds ratio

← Lower reported relative measureHigher reported relative measure →

incident hypertension0.4× 0.16 to 0.82×

0.25×0.5×No difference

Reported estimate95% confidence intervalEqual steps show equal ratios

The interval lies below no difference. This shows the direction under the reported model, not proof that the study is free of bias.

The confidence interval describes statistical uncertainty under the model, not every possible source of error.

Paper abstract · Abstract

Read the source context

The source behind this result.

The excerpt can discuss several outcomes or treatments. It is source context, not a reviewed conclusion about this single comparison.

Read reported excerpt

No significant association between incident hypertension and GLP-1RAs was detected, except for the association between exenatide-10 μg-twice-daily and sulfonylureas (OR, 0.40, 95% CI: 0.16, 0.82).

Paper abstract · Abstract

Automated source matching has not been reviewed by a scientific expert. This comparison's assignment method is not established.

Keep the limits in view

No significant association between incident hypertension and GLP-1RAs was detected, except for the association between exenatide-10 μg-twice-daily and sulfonylureas (OR, 0.40, 95% CI: 0.16, 0.82).
Paper abstract · Abstract

Inspect the source trail for this comparison

Paper abstract ↗ · Abstractabstract · Matched to source text; not expert scientific review
No significant association between incident hypertension and GLP-1RAs was detected, except for the association between exenatide-10 μg-twice-daily and sulfonylureas (OR, 0.40, 95% CI: 0.16, 0.82).